(Q34452209)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

review article

1 reference

title

Principles of pharmaceutical management of spastic hypertonia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

author name string

Elovic E

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

publication date

1 November 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

Physical medicine and rehabilitation clinics of North America

4 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

page(s)

793-816, vii

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

Neurosurgical treatment of spasticity: selective posterior rhizotomy and intrathecal baclofen

4 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen in cerebral palsy movement disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Baclofen in the treatment of cerebral palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Continuous intrathecal baclofen infusion for spasticity of cerebral origin

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

“Presynaptic” inhibition in spasticity and the effect of β(4-chlorophenyl)Gaba

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Cannabinoids control spasticity and tremor in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Long-term intrathecal baclofen therapy in patients with intractable spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Use of botulinum toxin in stroke patients with severe upper limb spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A comparison of baclofen and diazepam in the treatment of spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal Fentanyl Alleviates Spasticity in the Presence of Tolerance to Intrathecal Baclofen

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

The Effects of Dantrolene Sodium on Spasticity and Motor Performance in Hemiplegia

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Tizanidine (DS103-282), a centrally acting muscle relaxant, selectively depresses excitation of feline dorsal horn neurones to noxious peripheral stimuli by an action at α2-adrenoceptors

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Normal and impaired regulation of muscle stiffness in gait: a new hypothesis about muscle hypertonia

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen for spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Gabapentin for relief of spasticity associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Control of spasticity by implantable continuous flow morphine pump

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Control of intractable spasticity with intrathecal morphine sulfate

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Baclofen for spasticity in multiple sclerosis Double-blind crossover and three-year study

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

The effect of dantrolene sodium on spasticity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effect on ambulation of continuous intrathecal baclofen infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Common drugs may influence motor recovery after stroke. The Sygen In Acute Stroke Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin for spasticity and athetosis in children with cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Management of spasticity in children: part 2: oral medications and intrathecal baclofen

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Recommendations for the use of botulinum toxin type A in the management of cerebral palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Death after acute withdrawal of intrathecal baclofen: case report and literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Gabapentin for the treatment of spasticity in patients with spinal cord injury

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Ankle muscle activity before and after botulinum toxin therapy for lower limb extensor spasticity in chronic hemiparetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Baclofen in the Treatment of Spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A new agent for the control of spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Antinociceptive action of tizanidine in mice and rats

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Treatment alternatives for spinal cord injury related spasticity.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Epileptic seizures associated with intrathecal baclofen application

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Pharmacotherapy of spasticity: oral medications and intrathecal baclofen

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Post-Stroke Spasticity Management with Repeated Botulinum Toxin Injections in the Upper Limb

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Treatment of cerebral palsy with botulinum toxin A: functional benefit and reduction of disability. Three case reports

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Sprouting as a cause of spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Multiple sclerosis: symptomatic therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Prospective study on the use of bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Continuously infused intrathecal baclofen for spastic/dystonic hemiplegia: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: a preliminary report.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Tizanidine in the treatment of spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Peripheral and central effect of baclofen on ankle joint stiffness in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Baclofen increases the soleus stretch reflex threshold in the early swing phase during walking in spastic multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effect of baclofen on gait in spastic MS patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Gaba derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba).

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen for severe spasticity.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen for spasticity of spinal origin: seven years of experience

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen alleviates spinal cord spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Continuous intrathecal baclofen for severe spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Long-term intrathecal baclofen infusion for treatment of spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Intrathecal baclofen for severe spinal spasticity

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Phenol block of the tibial nerve for spasticity: a long-term follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effectiveness of gabapentin in controlling spasticity: a quantitative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

The ankle stretch reflexes in normal and spastic subjects. The response to sinusoidal movement.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effects of intrathecal clonidine injection on spinal reflexes and human locomotion in incomplete paraplegic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin injection of spastic finger flexors in hemiplegic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Clonidine in the treatment of brainstem spasticity. Case report

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Systemic toxicity of botulinum toxin by intramuscular injection in the monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effect of Dantrolene Sodium on Spasticity Associated with Hemiplegia†

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Cost analysis of continuous intrathecal baclofen versus selective functional posterior rhizotomy in the treatment of spastic quadriplegia associated with cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Complications of intrathecal baclofen delivery

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Treatment of Spasticity in Multiple Sclerosis With Dantrolene

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Oral Diazepam in the Treatment of Spasticity in Paraplegia a Double-Blind Trial and Subsequent Impressions

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Use of botulinum toxin injection in 17 children with spastic cerebral palsy

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Effect of transdermal clonidine on spinal spasticity. A case series

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance

1 reference

https://api.crossref.org/works/10.1016%2FS1047-9651%2818%2930033-0

7 January 2021

10.1016/S1047-9651(18)30033-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11727721%20AND%20SRC:MED&resulttype=core&format=json

4 December 2019

1 reference